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Key points 
 
Question: Does genetically-elevated Lipoprotein(a) (Lp[a]) predict calcific aortic valve stenosis 
(CAVS) in patients independently of coronary artery disease (CAD) and do first-degree relatives 
of patients with CAVS and high Lp(a) levels are more likely to be characterized by aortic valve 
microcalcification?  
 
Findings: Genetically-elevated Lp(a) was strongly association with CAVS, regardless of the 
presence/absence of CAD and first-degree relatives of patients with CAVS and high Lp(a) levels 
were more likely to have CAVS and/or aortic valve microcalcification.  
 
Meaning: Lp(a) is an independent risk factor for CAVS and measuring Lp(a) could be useful to 
identify individuals at risk of future CAVS.  
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Abstract 
 
Importance: Genetic variants at the LPA locus are associated with both calcific aortic valve 
stenosis (CAVS) and coronary artery disease (CAD). Whether these variants predict CAVS in 
patients with versus without CAD is unknown. 
 
Objectives: 1) To test the association between LPA variants and CAVS in a cohort of patients 
undergoing heart surgery, 2) to study the association between LPA and CAVS in patients with 
vs. without CAD and 3) to determine whether first-degree relatives of patients with CAVS and 
high lipoprotein(a) (Lp[a]) levels showed evidence of aortic valve microcalcification.  
 
Design: Genetic association study and family study.  
 
Setting: The genetic association study includes patients undergoing cardiac surgery or 
participants from the general population and the family study includes first-degree relatives of 
patients with CAVS. 
 
Participants: 1009 CAVS cases and 1017 controls undergoing cardiac surgery, 3258 cases and 
41,100 controls with CAD, 2069 cases and 380,075 controls without CAD and 33 first-degree 
relatives of 17 patients with both CAVS and high Lp(a) (≥125 nmol/L) and 23 controls with Lp(a) 
levels (<125 nmol/L).  
 
Exposures: Case-control studies.  
 
Main Outcomes and Measures: Presence of CAVS according to a weighted genetic risk score 
(wGRS) based on three common Lp(a)-raising variants and presence of aortic valve 
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microcalcification, defined as the mean tissue-to-background ratio (TBR) ≥1.25 measured by 
18F-NaF positron emission tomography/computed tomography.  
 
Results: In QUEBEC-CAVS, each SD increase of the GRS was associated with a higher risk of 
CAVS [OR=1.35 (95% CI: 1.10-1.66), P=0.003]. Each SD increase of the GRS was associated 
with a higher risk of CAVS in patients with CAD [OR=1.30 (95% CI: 1.20-1.42), P<0.001] and 
without CAD [OR=1.33 (95% CI: 1.14-1.55), P<0.001]. The percentage of individuals with a 
TBR≥1.25 or CAVS was higher in first-degree relatives of patients with CAVS (48.5%) and high 
Lp(a) compared to controls (13%, p=0.006).  
 
Conclusions and Relevance: Genetically elevated Lp(a) level is associated with CAVS, 
independently of the presence/absence of CAD. First-degree relatives of patients with CAVS 
and high Lp(a) show evidence of aortic valve microcalcification, a finding that supports further 
research on the potential usefulness of cascade screening in this population.  
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Introduction 
 
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein particle that consists of a cholesterol rich 
particle analogous to low-density lipoprotein (LDL), where apolipoprotein B-100 is linked to 
apo(a) by a disulfide bond (1). In contrast to LDL, the Lp(a) particle carries a substantial amount 
of pro-inflammatory and pro-calcifying oxidized phospholipids (OxPL), which bind to both the 
apo(a) and the LDL moieties of Lp(a) (2). The circulating level of Lp(a) is largely determined by 
genetic variation at the LPA locus, which is highly polymorphic. One of the strongest 
determinants of Lp(a) levels is a copy number variation (CNV) at this locus encoding Kringle IV – 
type 2 (KIV-2) repeats, which influence the length of apo(a) (smaller isoform size being linked to 
higher plasma Lp(a) levels) (3). It has been estimated that up to 70-90% of the variance in 
circulating Lp(a) may be explained by genetic variations at the LPA locus (4).  
 
Approximately 10 years ago, a series of genetic association studies revealed an association 
between variants associated with high Lp(a) levels and the risk of coronary artery disease (CAD) 
(5-7). Subsequent characterization of the LPA locus and it association with CAD risk makes it 
one of the strongest, most consistent and best-characterized locus associated with CAD risk 
(8,9). Investigating the genetics of aortic valve calcium (AVC), Thanassoulis et al. (10) identified 
LPA as the strongest genetic factor associated with the presence of AVC in an analysis of the 
Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) consortium. 
Population-based studies and hospital cohorts later revealed a strong link between Lp(a) and 
calcific aortic valve stenosis (CAVS) risk and progression (11-14).  
 
CAVS is the most common form of valvular heart disease and its prevalence is steadily 
increasing in Western societies, affecting approximately 2% of the population older than 65 (15). 
Similar to atherosclerotic cardiovascular diseases, the molecular mechanisms that initiate CAVS 
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include infiltration of oxidized lipids and lipoproteins (such as oxLDL and Lp[a]) and inflammatory 
cells (such as macrophages and T cells) as well as extra-cellular matrix remodeling and 
calcification. CAD and CAVS also share similar clinical risk factors such as male sex, age, 
smoking, type 2 diabetes, hypercholesterolemia and elevated Lp(a). Results of our recent 
analysis also suggested that risk factors associated with ideal cardiovascular health (an 
unhealthy diet, physical inactivity, smoking, obesity, type 2 diabetes, hypertension and 
hypercholesterolemia), often referred to as Life’s Simple 7, were associated with CAVS 
incidence in a large population-based study (16). While there is considerable overlap between 
pathobiological mechanisms and clinical risk factors between CAD and CAVS, whether this 
overlap also exists for genetic factors is currently unknown. Also unknown is whether the 
association between genetically-elevated Lp(a) levels and CAVS is independent of the presence 
of CAD is unknown. 
 
Although, the association between Lp(a) and CAVS is strong and consistent, there is currently 
little evidence supporting the routine assessment of Lp(a) levels in patients with CAVS. Routine 
measurement of Lp(a) levels in patients with CAVS could assist in the identification of family 
members of patients with CAVS and high Lp(a) levels who could be at increased risk of 
developing CAVS in the future. Whether first-degree relatives of patients with CAVS and high 
Lp(a) levels may show early signs of aortic valve disease or are at increased CAVS risk is 
unknown.  
 
The objective of this study was to 1) determine the association between genetically elevated 
Lp(a) levels and CAVS in a cohort of patients undergoing a heart surgery (including controls with 
CAD), 2) determine whether the association between genetically elevated Lp(a) levels and 
CAVS was observed in patients with and without CAD and 3) to determine whether first-degree 
relatives of patients with CAVS and high Lp(a) levels were characterized by aortic valve macro 
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or microcalcification assessed by a newly developed aortic valve imaging technique that assess 






Study populations  
This analysis includes 1009 cases and 1017 controls from the QUEBEC-CAVS study, 1350 
cases and 349,043 controls from the UK Biobank, 508 cases and 20,421 controls from the 
EPIC-Norfolk study, 3469 cases and 51,711 controls from the GERA study as well as 3123 
cases and 6530 control from three French cohorts. The characteristics of these cohorts are 
described in detail in the Supplementary data file. In the QUEBEC-CAVS cohort, patients with a 
history of myocardial infarction, coronary artery stenosis on coronary angiography, or 
documented myocardial ischemia were included in the CAD group. In the UK Biobank, patients 
with self-reported myocardial infarction (n=950), CAD from ICD or OPCS codes (n=25,162) were 
included in the CAD group. In the EPIC-Norfolk study, patients with documented myocardial 
ischemia or myocardial infarction or other ischemic heart disease on hospital admission were 
included in the CAD group. In GERA, CAD cases were defined using a diagnosis of myocardial 
infarction or CAD (ICD9 410-414); procedure codes for percutaneous coronary intervention or 
coronary artery bypass surgery. 
 
The design and characteristics of the family study is also described in the Supplementary data 
file. Briefly, a series of consecutive patients with mild to severe CAVS who did not undergo AVR 
were recruited at the echocardiography lab of the IUCPQ. Lp(a) levels were measured in 
patients with CAVS and first-degree relatives of patients with CAVS and Lp(a) levels ≥125 
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nmol/L (brothers, sisters or children aged above 40) as well as a control group of participants 
with Lp(a) levels <125 nmol/L unrelated to patients with CAVS underwent aortic valve 
microcalcification assessment, as described in the Supplementary data file. 
 
Genotyping, single-nucleotide polymorphisms selection and Lipoprotein(a) measurements 
The associations between the selected single nucleotide polymorphism (SNPs) and Lp(a) levels 
were obtained from the study of Emdin et al. (8) in which SNPs effect on Lp(a) levels were 
estimated in European ancestry in the ARIC cohort (n= 2,758). SNPs that were selected for this 
study are presented in Supplementary Table 1. Beta coefficients are expressed in 1 SD (28 
mg/dl) increase of Lp(a) level. We selected SNPs with a minor allele frequency superior to 1%. 
Only two SNPs (rs10455872, rs3798220) were available from the EPIC-Norfolk study. A 
weighted genetic risk score (wGRS) was calculated in each cohort by adding the number of 
Lp(a) raising alleles that the person had inherited at each variant that was included in the score, 
weighted by the effect of each variant on Lp(a) levels reported by Emdin et al. (8). In the family 
study, plasma Lp(a) levels were measured by a turbidimetric assay using the Tina-quant 
Lipoprotein(a) Gen.2 system (Cobas integra 400/800, Roche Diagnostics, Mannheim, Germany).  
 
Statistical analyses 
Participants characteristics were summarized by disease status for each study, and differences 
were assessed using two sample t-test or Pearson’s chi-square test for continuous and discrete 
characteristics, respectively. Welch’s t-test were used for samples who have unequal variances 
tested with F-test. All continuous variables were tested for normal distribution with the Shapiro-
Wilk test. In cases the null hypothesis that the data are normally distributed was rejected, the 
data were log transformed for statistical analyses and presented as the median and interquartile 
range. The association between the wGRS and CAVS was tested using logistic regression 
analyses that were adjusted for age, sex and principal components, when available. In the 
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GERA cohort, genetic variants were modelled using PLINK2 in logistic regression models 
adjusted for age, age squared, sex and the 10 principle components. We performed a random-
effect meta-analysis using the inverse-variance weighted method as implemented in rmeta 
package version 3.0 in R version 3.5.1. Sensitivity analysis were performed in the QUEBEC-
CAVS cohort using only participants with CAVS and CAD compared to controls with CAD, and in 
the other cohorts using participants with CAVS with/without CAD compared to controls 
with/without CAD (except for the French cohort which did not had CAD status in controls). The 
frequency of participant with CAVS and TBR ≥1.25 in first-degree relative compared to controls 
with low Lp(a) levels were assessed using Pearson’s chi-square test and the differences in 
mean TBR between first-degree relatives and participants in the control group were tested using 





Genetic association study 
The association between the LPA wGRS and CAVS is presented in Figure 1. In QUEBEC-
CAVS, each SD increase of the GRS was associated with a higher risk of CAVS [OR=1.35 (95% 
CI: 1.10-1.66), P=0.003]. The wGRS was also positively associated with CAVS in sensitivity 
analyses performed in patients with (3258 cases and 41,100 controls) and without CAD (2069 
cases and 380,075) in cohorts who included individuals with and without CAD. Each SD 
increase of the wGRS was associated with a higher risk of CAVS in patients with CAD [OR=1.30 
(95% CI: 1.20-1.42), P<0.001] and without CAD [OR=1.33 (95% CI: 1.14-1.55), P<0.001]. In the 
QUEBEC-CAVS cohort, each SD increase of the wGRS was associated with a higher risk of 
CAVS in patients with CAD only [OR=1.68 (95% CI: 1.33-2.12), P<0.001]. That analysis included 
586 cases and 989 controls, all with CAD.  
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Because CAD status was not available for controls included in the French cohort, results of the 
French populations are not presented in this sensitivity analysis (Figure 1). The association 
between the LPA wGRS and CAVS in cases of the French population stratified on the 
presence/absence of CAD is presented in Figure 2. This analysis shows that the wGRS is 
associated with CAVS in patients with both CAVS and CAD [OR=1.69 (95% CI: 1.35-2.12), 
P<0.001] and in patients with CAVS only [OR=1.60 (95% CI: 1.18-2.16), P<0.001] compared to 
population controls.  
 
Family study 
The clinical characteristics of the 17 patients with CAVS, 33 of their first-degree relatives 
(including 6 with CAVS and 27 without CAVS) and a control group of 23 individuals with low 
Lp(a) levels is presented in Table 1. Clinical characteristics of first-degree relatives and controls 
with low Lp(a) levels were comparable, except for the percentage of CAD, lipoprotein(a) levels, 
transvalvular pressure gradients and aortic valve area.  
 
The percentage of participants with either CAVS or a TBR≥1.25 among first-degree relatives of 
patients with CAVS and high Lp(a) levels and the control groups is presented in Figure 3A. The 
percentage of individuals with a TBR≥1.25 or CAVS was higher in first-degree relatives of 
patients with CAVS (48.5%) and high Lp(a) compared to controls (13%, p=0.006). No 
differences between the two groups were observed when we evaluated AVC for 18F-NF PET/CT 
by CT in first-degree relatives (data not shown). After excluding first-degree relatives with CAVS, 
the mean TBR of first-degree relatives (without CAVS) was higher compared to controls with low 
Lp(a) levels (Figure 3B).  
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Discussion 
 
In this study, we found that genetic variation at the LPA locus associated with higher Lp(a) levels 
was strongly associated with CAVS risk in patients undergoing cardiac surgery. Investigating the 
association between a wGRS associated with high Lp(a) levels in four CAVS cohorts stratified 
for the presence of CAD, we found that the association between genetically-elevated Lp(a) 
levels and CAVS was independent of CAD status. Results of this study support the notion that 
the association between Lp(a) and CAVS is not mediated by the concomitant presence of CAD 
and that individuals with high Lp(a) levels might have high CAVS risk, even if they do not have 
CAD. In a proof-of-concept study, we found that first-degree relatives of patients with CAVS and 
elevated Lp(a) levels may be at higher risk of aortic valve microcalcification measured by 18F-
NaF PET/CT compared to controls with lower Lp(a) levels. These results consolidate the strong 
and independent association of Lp(a) with CAVS and support further research about the 
potential usefulness of routine measurement of Lp(a) levels in patients with CAVS and cascade 
screening for Lp(a) in the setting of CAVS (Figure 4).  
 
It is well recognized that the presence of CAD might influence symptomatology of CAVS and 
therefore the diagnosis of the disease, which is an important aspect to consider in genetic 
association studies of CAVS. Indeed, patients with CAD may become symptomatic at the stage 
of moderate aortic stenosis, whereas patients with severe aortic stenosis may remain 
asymptomatic in the absence of CAD. Another potential confounding factor is concomitant AVR 
of a severe or moderate CAVS in patients undergoing coronary artery bypass surgery. In the 
setting of moderate aortic stenosis, AVR is thus generally driven by the diagnosis of CAD and 
indication of coronary artery bypass. It must be recognized however that the presence of CAD 
relied on data from electronic medical records and was not validated by an independent 
committee in most of the cohorts. Additionally, study participants with subclinical CAD or 
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symptomatic CAD without hospitalization might not have been captured in several cohorts and 
could have been assigned to the non-CAD group. Combined with previous work supporting a 
potentially causal role for Lp(a) in the etiology of CAD (5,17), our finding that genetically elevated 
Lp(a) levels predict CAVS irrespective of the presence/absence of CAD support the notion that 
Lp(a) might be a strong risk factor and an important trigger for both coronary artery- and aortic 
valve diseases. Altogether, these observations provide additional support to the hypothesis that 
Lp(a) may represent a therapeutic target of interest for CAVS.  
 
CAVS is a complex disease that was once thought to be the result of naturally occurring 
degenerative processes associated with aging. However, results of molecular and genetic 
association studies suggest that calcification of the aortic valve is a very tightly regulated 
process and that both genetic and environmental factors are pivotal for these processes (18). 
Imaging studies have also shown that years before the appearance of aortic calcification and 
anatomical disturbances of the aortic valve, the aortic valve may undergo a series of pro-
inflammatory and osteogenic processes associated with early CAVS (19). The most compelling 
evidence that highlighted a genetic component in CAVS came from two studies performed in 
France investigating the regional distribution of patients undergoing aortic valve replacement 
and the familial aggregation of the disease concluded that CAVS has a strong genetic basis 
(20,21). More recently, Martinsson et al. (22) reported the results of a very large investigation of 
more than 6 million Swedish siblings and showed that the odds of developing CAVS were 3-fold 
higher if one had a sibling with CAVS and more than 30-fold higher if one had two siblings with 
CAVS. The association between Lp(a) levels and family risk of CAVS was however not reported 
in these studies. Another recent investigation by Verweij et al. (23) included patients with 
atherosclerotic cardiovascular diseases (ASCVD) and their first-degree relatives and found that 
first-degree relatives of patients with ASCVD and Lp(a) levels ≥50 mg/dL (approximately 125 
nmol/L) were twice as likely to be characterized by coronary artery calcium accumulation or to 
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have had a cardiovascular event compared to those with lower Lp(a) levels. The link between 
Lp(a) levels and AVC accumulation was not reported in this family study.   
 
The National Heart, Lung and Blood Institute Working Group to Reduce Lp(a)-Mediated Risk of 
CAD and CAVS recently included in its top priorities for Lp(a) research that clinical CAVS 
studies be performed to evaluate the role of Lp(a) in calcification with established techniques or 
with emerging techniques such as 18F-NaF PET/CT (24). Although previous studies have linked 
Lp(a) with aortic valve macrocalcification measured by CT (10,25), in this study, we used 18F-
NaF PET/CT to assess microcalcification in first-degree relatives of patients with CAVS and high 
Lp(a) levels. The degree of CT-measured valve calcification reflects the amount of calcium 
regardless of when and at which rate the mineralization occurred in the course of CAVS, 
whereas the 18F-NaF PET/CT estimates the active mineral deposition in the aortic valve at a 
given time point. Therefore, in contrast to CT, which detects quiescent macrocalcification, 18F-
NaF PET/CT binds to active calcified nodules through chemical reactions with hydroxyapatite, a 
crystalline structure of calcium and phosphates (26). This technique is accurate and reproducible 
to detect and quantify inflammation (18F-fluorodeoxyglucose uptake) and mineralization activity 
(18F-NaF uptake into aortic valve hydroxyapatite) (27-30). Both mineralization and inflammation 
are increased in patients with versus without CAVS, and the activity of both rises steadily with 
increasing disease severity, as recently described by Dweck et al (27). However, mineralization 
is the culprit pathological process of CAVS and the measurement of valvular 18F-NaF uptake by 
PET/CT might provide a novel biomarker of early disease activity and progression. Although 
active microcalcification assessed by 18F-NaF PET/CT is a predictor of future AVC, it must be 
emphasized that although our findings suggest that first-degree relatives of patients with CAVS 
and high Lp(a) levels have higher odds of being characterized by active microcalcification 
compared to controls with low Lp(a) levels, it is not possible to determine how many of them will 
show accumulation of AVC or develop clinically significant CAVS in the future. Long-term follow-
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up of these individuals will help determine whether active microcalcification, in the setting of high 
Lp(a) levels will translate into macroscopic AVC accumulation measured by CT. Additionally, 
because of our limited samples size, we could not determine whether these individuals have 
higher levels of aortic valve microcalcification because they have high Lp(a) levels on average or 
because they have family history of CAVS.  
 
In an effort to identify patients with high Lp(a) levels who may be at risk, the European 
Atherosclerosis Society Consensus Panel recommended measuring Lp(a) levels in individuals 
with premature CAD (or with a family history of premature CAD), familial hypercholesterolemia, 
recurrent CAD despite statin treatment or intermediate cardiovascular risk (31). Although it is 
tempting to suggest that Lp(a) levels should be assessed routinely in patients with CAVS, in the 
absence of guidelines about specific actions to be taken once a patient with CAVS and high 
Lp(a) is identified, this recommendation would be premature. CAVS is the most common form of 
heart valve diseases. Surgical replacement of the aortic valve is the only effective treatment for 
CAVS. Given the strong association between Lp(a) and CAVS risk (independent of the 
presence/absence of CAD), determining whether lowering Lp(a) levels in patients with mild-to-
moderate CAVS would reduce the progression of CAVS or risk of future AVR for severe CAVS 
would be the ultimate proof of causal association between Lp(a) and CAVS while simultaneously 
opening new therapeutic options to treat patients with CAVS and high Lp(a) levels. Results of 
our study reinforce the notion that cascade screening for Lp(a) (the measurement Lp(a) levels in 
patients with CAVS as well as in their first-degree relatives) could be clinically useful. In light of 
failed statin trials in CAVS, whether targeting Lp(a) levels in these individuals would reduce 
future AVC accumulation or long-term CAVS risk should be tested in further studies. To our 
knowledge, only one agent (an antisense oligonucleotide targeting LPA) specifically designed to 
lower Lp(a) levels has been tested in a RCT. Viney et al. (32) reported that treatment with 
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AKCEA-APO(A)LRX was associated with a dose-response reduction in plasma Lp(a) levels of up 
to 80-90% in healthy individuals with Lp(a) levels equal or above 60 mg/dL.  
 
In conclusion, this investigation provides new genetic findings supporting an important role of 
Lp(a) in the aetiology of CAVS that is independent of the presence/absence of CAD. Although 
the impact of Lp(a)-lowering in patients with mild-to-moderate CAVS or patients at high CAVS 
risk still has to be established, our results provide evidence that the routine assessment of Lp(a) 
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Table 1. Clinical characteristics of patients with CAVS, their first-degree relatives including those 









Controls with low 
Lp(a) levels 
n 17 33 27 23 
Age (year) 71.6 (7.7) 63.9 (8.8) 63.1 (8.7) 60.6 (5.8) 
Male 64.7 (11) 66.7 (22) 63.0 (17) 60.9 (14) 
Body mass index (kg/m2) 30.8 (5.4) 29.3 (4.8) 29.4 (5.1) 28.1 (4.5) 
Hypertension 94.1 (16) 54.6 (18) 51.9 (14) 34.8 (8) 
Diabetes mellitus 23.5 (4) 18.2 (6) 14.8 (4) 8.7 (2) 
Coronary artery disease 64.7 (11) 24.2 (8)* 22.2 (6) 4.4 (1) 
Stroke 0 (0) 0 (0) 0 (0) 4.4 (1) 
Active smokers 0 (0) 9.1 (3) 11.1 (3) 13.0 (3) 
Lipid-lowering therapy 70.6 (12) 54.6 (18) 51.9 (14) 34.8 (8) 
Aortic valve peak gradient (mmHg) 38.9 (17.3) 17.3 (16.9)* 10.3 (4.8)# 7.7 (2.4) 
Aortic valve mean gradient 
(mmHg) 
21.8 (10.5) 9.4 (9.6)* 5.4 (2.6)# 4.2 (1.3) 










Data are presented as mean (SD), % (n) or median (IQR) 
* p<0.05 for First-degree relatives vs controls with low Lp(a) 
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Figures Legend 
 
Figure 1. Association of genetically-elevated Lp(a) levels with calcific aortic valve stenosis in 
patients with and without coronary artery disease. 
 
Figure 2. Association of genetically-elevated Lp(a) levels with calcific aortic valve stenosis in 
patients with and without coronary artery disease in participants of the French cohorts compared 
to controls (with unknown CAD status). 
 
Figure 3. Distribution of participants with calcific aortic valve stenosis or tissue-to-background 
ratio ≥1.25 in the family study (A) and mean aortic valve tissue-to-background ratio in first 
degree relatives without CAVS and controls with low Lp(a) levels (B). 
 
Figure 4. Results of this study that included cohorts from four countries suggest that the 
association between genetically elevated Lipoprotein(a) levels and calcific aortic valve stenosis 
is comparable in patients with versus without coronary artery disease and that first-degree 
relatives of patients with high Lipoprotein(a) levels and calcific aortic valve stenosis may have 
higher aortic valve calcification and could be at higher future risk of aortic valve calcification or 
calcific aortic valve stenosis.  
 
